NVS - Novartis AG

NYSE - NYSE Delayed price. Currency in USD
87.57
-0.28 (-0.32%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close87.85
Open87.46
Bid87.35 x 900
Ask88.87 x 800
Day's range87.39 - 88.07
52-week range69.18 - 99.84
Volume1,098,513
Avg. volume1,950,837
Market cap200.914B
Beta (5Y monthly)0.46
PE ratio (TTM)16.64
EPS (TTM)5.26
Earnings dateN/A
Forward dividend & yield3.09 (3.53%)
Ex-dividend date03 Mar 2020
1y target est104.00
  • Amgen Gets Favorable Appeals Court Ruling for Enbrel Patent
    Zacks

    Amgen Gets Favorable Appeals Court Ruling for Enbrel Patent

    An appeals court ruled in Amgen's (AMGN) favor in a case challenging the validity of two patents on its top-selling medicine, Enbrel.

  • Financial Times

    Novartis reaches $642m settlement with US authorities

    The Swiss pharmaceuticals group Novartis has agreed to pay $642m in settlements over claims it paid kickbacks to doctors and improperly funded purchases of its own drugs by patients receiving US government health benefits. The deal settles civil allegations against its US arm, Novartis Pharmaceuticals Corporation, and is the company’s third big resolution with US authorities in recent months. Last week Novartis, along with a current and a former subsidiary, agreed to pay a total of $347m to settle US criminal and civil foreign bribery investigations.

  • Novartis pays $729 mln in U.S. kickback charges
    Reuters Videos

    Novartis pays $729 mln in U.S. kickback charges

    Illegal kickbacks to doctors and patients to boost drug sales. That's landed drugmaker Novartis with more than 729 million dollars in charges to the U.S. department of justice. Under the settlement announced on Wednesday (July 1) Novartis will pay $678 million to resolve claims it organised tens of thousands of sham educational events. During these gatherings, doctors were lavished with exorbitant speaker fees, expensive dinners and alcohol, in a bid to induce them to prescribe its cardiovascular and diabetes drugs more often. Novartis will also pay $51.25 million to resolve charges it funneled money through three charitable foundations to cover co-payments of Medicare patients so they would purchase its drugs. The Justice Department said the speaker programs and other promotional events occurred between 2002 to 2011. The co-payments were made between 2010 to 2014. Novartis has agreed to stop its speaker programs and enter a five-year corporate integrity agreement. In a statement it said "We are a different company today -- with new leadership, a stronger culture and a more comprehensive commitment to ethics"

  • Investing.com

    Stocks - Europe Seen Higher on Virus Vaccine Optimism

    Elsewhere, gold futures fell 0.2% to $1,776.35/oz, while EUR/USD traded at 1.1270, up 0.2% on the day.

  • Amgen's Win, Netflix's Hire Send Nasdaq Higher
    Motley Fool

    Amgen's Win, Netflix's Hire Send Nasdaq Higher

    The first half of 2020 was turbulent, but it was generally good to the Nasdaq stock market, and that momentum continued on the first day of July. The Nasdaq Composite (NASDAQINDEX: ^IXIC) and the Nasdaq 100 climbed around 1%, outpacing much of the rest of the market. Amgen (NASDAQ: AMGN) celebrated a valuable legal win, while Netflix (NASDAQ: NFLX) made a strategic hire and got praise from stock analysts.

  • Novartis Gets Positive CHMP View for Cosentyx Label Expansion
    Zacks

    Novartis Gets Positive CHMP View for Cosentyx Label Expansion

    Novartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.

  • Business Wire

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG – NVS

    Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that the board of directors of Novartis may have breached its fiduciary duties to shareholders.

  • Financial Times

    ESG strategies still buoyant despite Covid, say in-house lawyers

    The publishing group, known for its flagship Nature science journal, made thousands of articles from its journals and books freely available to help researchers get on top of the pandemic. The group is already a pioneer in open access publishing, making some content available online for free, but it had never acted quite on this scale before. Springer launched a learn-at-home platform to help teachers who suddenly found themselves trying to give lessons online.

  • Novartis, Units Admit Violating Bribery Law Bashed by Trump
    Bloomberg

    Novartis, Units Admit Violating Bribery Law Bashed by Trump

    (Bloomberg) -- The Swiss drugmaker Novartis AG and two subsidiaries admitted to overseas bribery schemes and agreed to pay about $347 million to settle U.S. investigations under a law that President Donald Trump has criticized as unfair.A Novartis unit in Greece bribed doctors and hospitals to prescribe its products, and Alcon, a unit that Novartis sold last year, kept false records to cover bribes paid to advance its business in Vietnam, according to U.S. authorities.“Novartis AG’s subsidiaries profited from bribes that induced medical professionals, hospitals, and clinics to prescribe Novartis-branded pharmaceuticals and use Alcon surgical products, and they falsified their books and records to conceal those bribes,” Assistant Attorney General Brian A. Benczkowski of the Justice Department’s Criminal Division said Thursday in a written statement.Novartis Chief Executive Officer Vas Narasimhan set out to rebuild the company’s reputation after revelations that it paid $1.2 million to Trump’s former lawyer, Michael Cohen, as well as earlier allegations of improperly paying thousands of doctors.Narasimhan took steps to raise standards and manage risk while also naming a new ethics chief. He said the company made a mistake in signing up Cohen, which came before he took over in 2018.Novartis shares rose less than 1% to $89.54 in New York, joining a late rally among U.S. stocks.Investigations under the U.S. Foreign Corrupt Practices Act have slowed since the 2016 election of Trump, who has called it a “horrible law.” In a 2017 Oval Office meeting, Trump ordered Secretary of State Rex Tillerson to abolish the law, according to a book by Washington Post reporters.“It’s just so unfair that American companies aren’t allowed to pay bribes to get business overseas,” Trump said, according to “A Very Stable Genius” by the reporters Philip Rucker and Carol D. Leonnig.In the deal announced on Thursday, Novartis Hellas S.A.C.I., the Greek unit, agreed to pay a criminal penalty of $225 million. Novartis AG will pay $112.8 million to the Securities and Exchange Commission. Alcon Pte Ltd., a former Novartis subsidiary, will pay a criminal fine of $8.9 million.Both the Greek unit and Alcon were charged with crimes in federal court in New Jersey, but prosecutors agreed to defer prosecution in exchange for commitments by the companies to reform their practices. The companies are cooperating with authorities. The conduct described by authorities dates back more than a decade.“We are pleased that all outstanding FCPA investigations into the company are now closed,” Shannon Thyme Klinger, Novartis’s group general counsel, said in a written statement. “Today’s settlements represent another milestone in our commitment to resolving legacy compliance issues and ensuring that Novartis truly lives its values.”Still, the drugmaker’s U.S. legal problems aren’t over. The U.S. sued the company seven years ago, joining in a case filed by a former sales representative who accused the company of using its speakers programs to pay kickbacks to doctors who prescribed its drugs.The lawsuit claims that Novartis paid thousands of doctors with speaking fees, fishing trips and even outings at Hooters restaurants to boost sales of hypertension drugs Lotrel and Valturna, along with the diabetes medication Starlix.Last year, the company set aside about $700 million for a potential settlement. The case is still pending.The settlements on Thursday were unrelated to the money paid to Cohen to enhance its understanding of and access to the Trump administration after his inauguration in January 2017. Novartis said it determined early on that Cohen wouldn’t be able to help with heath care policy matters, but it continued to make payments until the contract expired because it couldn’t be terminated for cause.Cohen pleaded guilty last year to tax evasion, making false statements to a bank, lying to Congress and violating campaign-finance law. He was sentenced to three years in prison and was recently released to his New York home because of the coronavirus pandemic.As part of the settlements on Thursday, prosecutors outlined a range of Novartis misdeeds.For instance, Novartis bribed eye doctors in Greece by paying for international conference sponsorships from 2012 to 2015 to boost sales of Lucentis, a drug to treat macular degeneration, according to an SEC order. The cost to attend these conferences often exceeded $5,000 per doctor. The company tied such payments to prescriptions and warned that trips would “be canceled if sales performance is not improved significantly.”MORE:Novartis’s Secret Settlement Talks Revealed in Accidental Filing(Updates with Novartis shares in the sixth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Novartis Discontinues HCQ Study Due to Enrollment Challenges
    Zacks

    Novartis Discontinues HCQ Study Due to Enrollment Challenges

    Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.

  • Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs
    Zacks

    Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs

    FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.

  • Coronavirus update: US sees steady resurgence as FDA puts nail in coffin of hydroxychloroquine debate
    Yahoo Finance

    Coronavirus update: US sees steady resurgence as FDA puts nail in coffin of hydroxychloroquine debate

    The coronavirus extended its grip across the world on Monday, as the FDA appeared to end the debate over a controversial drug.

  • Novartis' (NVS) Beovu Gets FDA Approval for Label Update
    Zacks

    Novartis' (NVS) Beovu Gets FDA Approval for Label Update

    Novartis' (NVS) ophthalmology drug, Beovu, gets update for safety information regarding retinal vasculitis and retinal vascular occlusion.

  • The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International
    Zacks

    The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International

    The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International

  • Top Stock Reports for Mastercard, Novartis & Boeing
    Zacks

    Top Stock Reports for Mastercard, Novartis & Boeing

    Top Stock Reports for Mastercard, Novartis & Boeing

  • Novartis' Asthma Treatment Meets Primary Endpoint in Phase III
    Zacks

    Novartis' Asthma Treatment Meets Primary Endpoint in Phase III

    Novartis (NVS) announces positive results from a late-stage study on Enerzair Breezhaler in patients with asthma.

  • Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals
    Zacks

    Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals

    Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.

  • Novartis (NVS) Announces Positive Data From Cosentyx Study
    Zacks

    Novartis (NVS) Announces Positive Data From Cosentyx Study

    Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.

  • Pliant Therapeutics Up 33% on IPO Pricing
    Motley Fool

    Pliant Therapeutics Up 33% on IPO Pricing

    Investors are excited about the biotech's prospects, but the company still has a long road ahead.

  • Novartis' sBLA for Ofatumumab Gets Extended Review From FDA
    Zacks

    Novartis' sBLA for Ofatumumab Gets Extended Review From FDA

    The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.

  • Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion
    Zacks

    Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion

    Novartis (NVS) gets positive CHMP opinion for breast cancer drug, Piqray. The company also announces other pipeline updates.

  • Novartis to Manufacture Mass General's Coronavirus Vaccine Candidate
    Motley Fool

    Novartis to Manufacture Mass General's Coronavirus Vaccine Candidate

    A subsidiary of the pharmaceutical giant will soon ramp up production of the nonprofit hospital's SARS-CoV-2 vaccine candidate, which has yet to enter human clinical trials.

  • Big Day for Data: GDP, Jobless Claims, Novartis, Durable Goods & More
    Zacks

    Big Day for Data: GDP, Jobless Claims, Novartis, Durable Goods & More

    Q1 GDP, Durable Goods and, of course, Initial Jobless Claims all hit the tape an hour before the bell, along with a new COVID-19 vaccine candidate and an executive order on social media.

  • Telehealth is going to 'become the default' for patients: Ro CEO
    Yahoo Finance

    Telehealth is going to 'become the default' for patients: Ro CEO

    Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.

  • Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA
    Zacks

    Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA

    Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.